In Re Lorazepam & Clorazepate Antitrust Litigation
Opinion for the Court filed by Circuit Judge ROGERS.
This appeal presents for the first time in this circuit the threshold question of when interlocutory review of a class certification decision is appropriate under
I.
The class action now pending in the district court was preceded by two lawsuits brought by the FTC and several States’ Attorneys General against Mylan that were ultimately consolidated and ended in a settlement. On December 21, 1998, the FTC filed suit, pursuant to §§ 5 and 13(b) of the Federal Trade Commission Act (“FTC Act”),
On August 16, 1999, the Judicial Panel on Multidistrict Litigation transferred to the United States District Court for the District of Columbia a Northern District of Illinois lawsuit pending against Mylan. This lawsuit was consolidated, on March 9, 2000, with a lawsuit brought by St. Charles Rehabilitation Center against Mylan. The named plaintiffs in the consolidated action were Advocate Health Care, St. Charles Hospital and Rehabilitation Center, Dik Drug Company, and Harvard Pilgrim Health Care, and they sought class certification as direct purchasers of lorazepam and clorazepate. The amended complaint alleged that Mylan had engaged in price
All persons and entities in the United Sates who purchased generic lorazepam tablets and/or generic clorazepate tablets directly from Defendants Mylan and UDL during the period January 12,1998 through the present, excluding Defendants, their respective parents, subsidiaries and affiliates, any co-conspirators of Defendants, and all governmental entities.
In re Lorazepam & Clorazepate Antitrust Litig.,
Mylan now petitions for interlocutory review of the district court’s denial of its
We first set forth the standards that we will ordinarily apply in exercising our discretion under
II.
Permission to appeal may be granted or denied on the basis of any consideration that the court of appeals finds persuasive. Permission is most likely to be granted when the certification decision turns on a novel or unsettled question of law, or when, as a practical matter, the decision on certification is likely dispositive of the litigation.
Id.
Thus, the advisory committee’s note identifies two instances in which
First among the circuits to address the scope of appellate review pursuant to
The First Circuit in
Waste Management Holdings, Inc. v. Mowbray,
While we hope that these general comments will be helpful to parties deciding whether to pursue applications underRule 23(f) , we do not foreclose the possibility that special circumstances may lead us either to deny leave to appeal in cases that seem superficially to fit into one of these three pigeonholes, or conversely, to grant leave to appeal in cases that do not match any of the three described categories.
Id.
Stating as well that it “intend[s] to exercise [its] discretion judiciously,” however, the First Circuit observed that “[b]y their nature, interlocutory appeals are disruptive, time-consuming, and expensive,” and that notwithstanding the access to the appellate courts provided by
Other circuits have elaborated on the
Mowbray
approach. The Eleventh Circuit, in
Prado-Steiman v. Bush,
The differences among the circuits, which are subtle, are of three types. First, two circuits permit appeal if the district court’s decision is erroneous, regardless whether the other factors governing appeal under
In our view, interlocutory appellate review under
With these considerations in mind, we offer the following guidance.
As is true for all the circuits, we are of the view that
III.
Mylan contends in its
A.
Although Mylan is correct that whether a class of direct purchasers has antitrust standing under the particular circumstances at issue is a novel question of law, the question is unrelated to class certification under
The cases on which Mylan relies do not advance its cause. To the extent that appellate courts have considered constitutional standing pursuant to
Although the question of whether a class of direct purchasers has antitrust standing when, in Mylan’s terms, “two antitrust cases collide” relates neither to this court’s subject matter jurisdiction nor to any aspect of
B.
Mylan’s challenge to the composition of the certified class as assertedly, and improperly, consisting of both direct and indirect purchasers also is inappropriate for
First, Mylan has not shown that certification of the class would sound the death knell of the litigation. Other than mere assertions, Mylan makes no showing that it will be unduly pressured to settle because of the class’s certification. Mylan failed to submit any evidence that the damages claimed would force a company of its size to settle without relation to the merits of the class’s claims.
See Prado-Steiman,
Third, Mylan has not made a showing that, in light of the district court’s discretion,
see Hartman v. Duffey,
Accordingly, we hold, upon applying the standards that we have outlined in defining when